Company intelligence / Profile preview
Asieris Pharmaceuticals
Shanghai, Shanghai, Chinaasieris.com ↗
- Ownership
- Private
- Employees
- ~61
- Development stage
- Other
01
Overview
APL-1702 succeeded in global Phase III clinical trials; APL-1706 (Hexvix®) obtained NDA acceptance domestically; Phase II clinical trial of APL-1202 in combination with PD-1 inhibitor tislelizumab for neoadjuvant therapy in muscle-invasive bladder cancer showed encouraging efficacy signals with a pCR rate of 41% compared to 20% for tislelizumab monotherapy
- Therapeutic areas
- Women's HealthOncologyGastroenterologyInfectious Diseases
- Modalities
- Small molecule drugsAntibody drug conjugates (ADC)Proteolysis-targeting chimeras (PROTAC)Photosensitizers
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
BeiGene (for tislelizumab)Photocure (for Cevira®)Sinopharm
Beyond the preview
Go deeper on Asieris Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asieris Pharmaceuticals.